Drug intelligence / Profile preview

GBS103

Development stage: Preclinical
Lead developer: Gb Sciences
Modality: Small Molecules
Administration: Oral

Overview

**GBS103** is a proprietary, preclinical cannabinoid- and terpenoid-containing complex mixture developed by GB Sciences for Parkinson's disease. It is one of three Parkinson's disease candidates evaluated for formulation in Catalent's Zydis orally disintegrating tablet platform. The active pharmaceutical ingredient comprises up to nine synergistic small-molecule components; the specific composition and direct molecular targets of GBS103 have not been publicly disclosed. ([gbsciences.com](https://www.gbsciences.com/2018/09/28/catalent/))

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on GBS103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBS103.

Explore the full profile